De Petris L, Crinò L, Scagliotti G V, Gridelli C, Galetta D, Metro G, Novello S, Maione P, Colucci G, de Marinis F
5th Pneumo-Oncology Unit, Deparment of Lung Diseases, S. Camillo-Forlanini Hospitals, Rome, Italy.
Ann Oncol. 2006 Mar;17 Suppl 2:ii36-41. doi: 10.1093/annonc/mdj919.
In the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early 90s there was still concern about the real efficacy of chemotherapy over best suppotive care alone in the advanced setting, constant developments in clinical research have demonstrated the survival advantage of active anti-cancer drugs not only in the first-line setting, but, lately, even in patients with recurrent disease after failure of two previous chemotherapy lines. With the premises of high throughput technologies, translational research is aiming to characterize patients and tumors on a molecular basis. With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients.
在过去十年中，晚期转移性非小细胞肺癌的治疗有了显著改善。如果说在90年代初，人们仍对晚期情况下单纯化疗相较于最佳支持治疗的实际疗效存在担忧，那么临床研究的不断发展已证明，活性抗癌药物不仅在一线治疗中具有生存优势，而且最近在经过两线先前化疗失败后的复发性疾病患者中也有生存优势。在高通量技术的前提下，转化研究旨在从分子层面表征患者和肿瘤。借助药物基因组学，就有可能准确预测患者的预后，并根据单个患者的基因表型调整治疗策略。
